Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Induction of fibroblast senescence generates a non-fibrogenic myofibroblast phenotype that differentially impacts on cancer prognosis.
Mellone M, Hanley CJ, Thirdborough S, Mellows T, Garcia E, Woo J, Tod J, Frampton S, Jenei V, Moutasim KA, Kabir TD, Brennan PA, Venturi G, Ford K, Herranz N, Lim KP, Clarke J, Lambert DW, Prime SS, Underwood TJ, Vijayanand P, Eliceiri KW, Woelk C, King EV, Gil J, Ottensmeier CH, Thomas GJ. Mellone M, et al. Among authors: ford k. Aging (Albany NY). 2016 Dec 15;9(1):114-132. doi: 10.18632/aging.101127. Aging (Albany NY). 2016. PMID: 27992856 Free PMC article.
Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4.
Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, Smith DM, Harden E, Szyndralewiez C, Bullock M, Noble F, Moutasim KA, King EV, Vijayanand P, Mirnezami AH, Underwood TJ, Ottensmeier CH, Thomas GJ. Hanley CJ, et al. Among authors: ford k. J Natl Cancer Inst. 2018 Jan 1;110(1):109-20. doi: 10.1093/jnci/djx121. J Natl Cancer Inst. 2018. PMID: 28922779 Free PMC article.
NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors.
Ford K, Hanley CJ, Mellone M, Szyndralewiez C, Heitz F, Wiesel P, Wood O, Machado M, Lopez MA, Ganesan AP, Wang C, Chakravarthy A, Fenton TR, King EV, Vijayanand P, Ottensmeier CH, Al-Shamkhani A, Savelyeva N, Thomas GJ. Ford K, et al. Cancer Res. 2020 May 1;80(9):1846-1860. doi: 10.1158/0008-5472.CAN-19-3158. Epub 2020 Mar 2. Cancer Res. 2020. PMID: 32122909 Free PMC article.
Pan-cancer deconvolution of tumour composition using DNA methylation.
Chakravarthy A, Furness A, Joshi K, Ghorani E, Ford K, Ward MJ, King EV, Lechner M, Marafioti T, Quezada SA, Thomas GJ, Feber A, Fenton TR. Chakravarthy A, et al. Among authors: ford k. Nat Commun. 2018 Aug 13;9(1):3220. doi: 10.1038/s41467-018-05570-1. Nat Commun. 2018. PMID: 30104673 Free PMC article.
Buserelin as primary therapy in advanced prostatic carcinoma.
Presant CA, Soloway MS, Klioze SS, Kosola JW, Yakabow AL, Mendez RG, Kennedy PS, Wyres MR, Naessig VL, Ford KS, et al. Presant CA, et al. Among authors: ford ks. Cancer. 1985 Nov 15;56(10):2416-9. doi: 10.1002/1097-0142(19851115)56:10<2416::aid-cncr2820561013>3.0.co;2-#. Cancer. 1985. PMID: 3930064
Invasive bladder cancer: support for screening.
Hopkins SC, Ford KS, Soloway MS. Hopkins SC, et al. Among authors: ford ks. J Urol. 1983 Jul;130(1):61-4. doi: 10.1016/s0022-5347(17)50953-2. J Urol. 1983. PMID: 6864916
1,137 results